9-Feb-2026 3:16 PM CST - Business Wire Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, 2026. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnsons Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be availa
21-Jan-2026 5:20 AM CST - Business Wire Johnson & Johnson reports Q4 and Full-Year 2025 results Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. 2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history, said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuros
2-Jan-2026 7:00 AM CST - Business Wire Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the companys common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare in
15-Dec-2025 3:27 PM CST - Business Wire Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson &
14-Oct-2025 5:21 AM CST - Business Wire Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business Johnson & Johnson (the Company) (NYSE: JNJ) today announced the Companys intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders. The intended separation would further strengthen the focus of Johnson & Johnson as an innovation powerhouse, serving areas of high unmet needs across Innovative Medicine and MedTech, accelerating the ongoing shift of the Companys MedT
14-Oct-2025 5:20 AM CST - Business Wire Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline, said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vis
6-Oct-2025 3:00 PM CST - Business Wire Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference Johnson & Johnson (NYSE: JNJ) will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Tuesday, November 11th, 2025. Management will participate in a Fireside Chat at 10:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnsons Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast re
30-Jul-2025 3:32 PM CST - Business Wire Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10th, 2025. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnsons Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay wi
16-Jul-2025 5:20 AM CST - Business Wire Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. Todays strong results reflect the depth and strength of Johnson & Johnsons uniquely diversified business operating across both MedTech and Innovative Medicine, said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and subm
Latest JNJ Trades by Congress Members
18-DEC-2025 - Julie Johnson, TX (District 32) sold between $1,001 and $15,000.
9-Feb-2026 3:16 PM CST - Business Wire Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, 2026. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnsons Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be availa
21-Jan-2026 5:20 AM CST - Business Wire Johnson & Johnson reports Q4 and Full-Year 2025 results Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. 2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history, said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuros
2-Jan-2026 7:00 AM CST - Business Wire Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the companys common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare in
15-Dec-2025 3:27 PM CST - Business Wire Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson &
14-Oct-2025 5:21 AM CST - Business Wire Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business Johnson & Johnson (the Company) (NYSE: JNJ) today announced the Companys intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders. The intended separation would further strengthen the focus of Johnson & Johnson as an innovation powerhouse, serving areas of high unmet needs across Innovative Medicine and MedTech, accelerating the ongoing shift of the Companys MedT
14-Oct-2025 5:20 AM CST - Business Wire Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline, said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vis
6-Oct-2025 3:00 PM CST - Business Wire Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference Johnson & Johnson (NYSE: JNJ) will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Tuesday, November 11th, 2025. Management will participate in a Fireside Chat at 10:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnsons Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast re
30-Jul-2025 3:32 PM CST - Business Wire Johnson & Johnson to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10th, 2025. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnsons Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay wi
16-Jul-2025 5:20 AM CST - Business Wire Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. Todays strong results reflect the depth and strength of Johnson & Johnsons uniquely diversified business operating across both MedTech and Innovative Medicine, said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and subm
